Repligen says planned tech launches and growing cell and gene therapy sector demand will drive market expansion and growth in 2020. The bioprocess and life science tech supplier shared its thoughts at the JP Morgan Healthcare conference. CEO Tony Hunt said a “surge†in clinical activity is driving expansion in the CDMO space – citing announcements by Catalent and Thermo Fisher Scientific – and at large pharma firms like Amgen, Novartis and BeiGene. “If you go back a few years…
Krystal Biotech has broken ground on a commercial gene therapy manufacturing facility in Findlay Township, Pennsylvania. The 100,000 square-foot ‘ASTRA’ facility, set to create 75 jobs in the Pennsylvanian town, is expected to open in late 2021 to support Krystal Biotech’s gene therapy pipeline. Krystal is developing several ‘off-the-shelf’ gene therapies for rare skin diseases using its Skin TARgeted Delivery (STAR-D) platform consisting of an engineered HSV-1 vector and skin optimized gene transfer technology. Lead candidate B-VEC (previously known as…
Ori Biotech estimates its automated and closed manufacturing platform can reduce COGS for autologous cell therapies by 60-80% and has teamed with HCATS to help take it to the clinic. One of the key takeaways from this year’s Phacilitate conference last week was the need for partnerships and collaboration to overcome the many issues currently plaguing the cell and gene therapy space, and specifically manufacturing. One such collaboration is between Hitachi Chemical Advanced Therapeutics Solutions (HCATS), the contract development and…